ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, today announced that it will release financial results for the fourth quarter and full year 2023 after the U.S. market close on Tuesday, March 12th, 2024. Company management will host a conferen ...

ROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancie ...

ROCKVILLE, Md., and SYDNEY, Australia, Jan. 23, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Imugene, (ASX: IMU), a clinical-stage immuno-oncology and cell therapy company developing a range of new treatments that seek to activate the immune system of ca ...

ROCKVILLE, Md. and SINGAPORE, Jan. 03, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, and Lion TCR, an Asia-based, clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-T cell therapies for solid tumors and life-threatening viral i ...

ROCKVILLE, Md., Jan. 01, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ:MXCT, LSE: MXCT))), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and innovative bioprocessing applications, is pleased to confirm the appointment of Maher Masoud as President and Chief Executive Officer of MaxCyte effective as of January 1, 2024. In addition, Mr. Masoud now serves as a director on Max ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the transition period from___ to___ Commission file number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark w ...

MaxCyte, Inc. (NASDAQ:MXCT) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Sean Menarguez - Head-IR Doug Doerfler - President and CEO Douglas Swirsky - CFO Conference Call Participants Julie Simmonds - Panmure Gordon Dan Arias - Stiefel Jacob Johnson - Stephens Madeline Mollman - William Blair Vidyun Bais - BTIG Steven Mah - TD Cowen Operator Thank you for standing by, and welcome to MaxCyte's Second Quarter 2023 Earnings Call. At this time, all participants are in a listen- ...

Table of Contents Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number: 001-40674 MaxCyte, Inc. (Exact name of registrant as specified in its charter) Delaware 52-2210438 (State or ...

MaxCyte, Inc. (NASDAQ:MXCT) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Sean Menarguez - Head-Investor Relations Doug Doerfler - President & Chief Executive Officer Douglas Swirsky - Chief Financial Office Conference Call Participants Julie Simmonds - Panmure Gordon Dan Arias - Stifel Hannah Hefley - Stephens Steven Mah - TD Cowen Madeline Mollman - William Blair Vidyun Bais - BTIG Operator Good day, and thank you for standing by and welcome to MaxCyte’s First Quarter Earn ...

Disclaimer Certain statements in this Presentation are, or may be deemed to be, forward looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1955, including but not limited to statements regarding our expected potential future revenue. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "targe ...